Bortezomib — Drug Intelligence | 70 EU Trials

Filter these 70 trials by condition, phase, country and more.

Open in Search →

70 Registered trials

18 Recruiting

47 Completed trials

39 Sponsors

23 Countries

Phase III

Phase II

Phase III: 32 Phase II/III: 1 Phase II: 32 Phase I/II: 2 Phase IV: 2 Phase I (FiH): 1

Oversight events:

1 serious breach 12 temporary halts 4 urgent safety measures 5 unexpected events 2 corrective measures across 13 trials

View oversight register →

Indications tested

Plasma cell myeloma 2 Encephalitis autoimmune 1 Primary amyloidosis 1 Malignant glioma 1 Hypophosphatasia 1 Waldenstrom's macroglobulinaemia 1

Sponsors using this IMP

Janssen - Cilag International 10 Fundacion PETHEMA 6 Emn Trial Office S.r.l. Impresa Sociale 5 European Myeloma Network B.V. 5 Celgene Corp. 4 Centre Hospitalier Universitaire De Nantes 3 Glaxosmithkline Research & Development Limited 3 Oslo University Hospital HF 3 Universitaetsklinikum Heidelberg AöR 3 AbbVie Deutschland GmbH & Co. KG 2 Ceska Myelomova Skupina z.s. 2 Hellenic Society Of Hematology 2

All trials

70 total

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Pending

2025-523117-28-00 Phase II 5 countries Glaxosmithkline Research & Development Limited
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending

2025-523285-25-00 Phase III 6 countries AstraZeneca AB
A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending

2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of… Recruiting

2024-517099-39-00 Phase II 1 country Centre Hospitalier Universitaire De Poitiers
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Phase III 1 country Intergroupe Francophone Du Myelome
Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting

2024-511188-26-00 Phase III 9 countries Kite Pharma Inc.
A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or … Recruiting

2023-507899-47-00 Phase II 1 country Goethe University Frankfurt
BORTEM 17 Recruiting

2024-515142-16-00 Phase I (FiH) 1 country Helse Bergen HF
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Phase III 16 countries Pfizer Inc.
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom… Recruiting

2023-507632-20-00 Phase III 9 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting

2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting

2022-500453-16-00 Phase II 1 country University Medical Centre Schleswig-Holstein
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit… Recruiting

2024-517382-17-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Phase III 12 countries Pfizer Inc.
An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit… Recruiting

2024-511635-94-00 Phase II 1 country Fondazione Italiana Linfomi Ets
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of … Recruiting

2024-518263-35-00 Phase II 1 country Hellenic Society Of Hematology
The SABLe study Recruiting

2024-512276-35-00 Phase II 3 countries Odense University Hospital
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting

2024-517215-67-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
Selinexor, Dexamethasone and Bortezomib in Patients with Multiple Myeloma Recruiting

2024-511608-18-00 Phase II 1 country Karyopharm Therapeutics Inc.
A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune … Recruiting

2024-514494-21-00 Phase II 1 country Friedrich-Schiller-Universitaet Jena
A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended

2024-517020-18-00 Phase II 1 country Fundacion PETHEMA
RElapse from Mrd Negativity As iNdication for Treatment Ended

2023-510215-18-00 Phase II/III 2 countries Oslo University Hospital HF

Showing 1–24 of 70 trials

← All drugs A–Z